Manufacturer of Controlled Substances; Notice of Registration, 48441 [05-16288]
Download as PDF
<![CDATA[
Federal Register / Vol. 70, No. 158 / Wednesday, August 17, 2005 / Notices
Commission’s electronic docket (EDIS)
at https://edis.usitc.gov.
SUPPLEMENTARY INFORMATION: On
August 5, 2005, the Commission
determined that it should proceed to
full reviews in the subject five-year
reviews pursuant to section 751(c)(5) of
the Act.1 The Commission found that
the domestic interested party group
response to its notice of institution (70
FR 22696, May 2, 2005) was adequate,
and that the respondent interested party
group response with respect to Korea
was adequate, but found that the
respondent interested party group
response with respect to Japan was
inadequate. However, the Commission
determined to conduct a full review
concerning subject imports from Japan
to promote administrative efficiency in
light of its decision to conduct a full
review with respect to subject imports
from Korea. A record of the
Commissioners’ votes, the
Commission’s statement on adequacy,
and any individual Commissioner’s
statements will be available from the
Office of the Secretary and at the
Commission’s Web site.
Drug
Normorphine (9313) .....................
Norlevorphanol (9634) ..................
Amphetamine (1100) ....................
Methamphetamine (1105) ............
Methylphenidate (1724) ................
Codeine (9050) .............................
Diprenorphine (9058) ....................
Etorphine HCL (9059) ..................
Dihydrocodeine (9120) .................
Hydromorphone (9150) ................
Oxycodone (9143) ........................
Diphenoxylate (9170) ...................
Benzoylecgonine (9180) ...............
Hydrocodone (9193) .....................
Levorphanol (9220) ......................
Meperidine (9230) ........................
Methadone (9250) ........................
Methadone Intermediate (9254) ...
Metopon (9260) ............................
Dextropropoxyphene (9273) .........
Morphine (9300) ...........................
Thebaine (9333) ...........................
Opium extracts (9610) ..................
Opium fluid extract (9620) ............
Opium tincture (9630) ...................
Opium, powdered (9639) ..............
Opium, granulated (9640) ............
Levo-alphacetylmethadol (9648) ..
Oxymorphone (9652) ....................
Noroxymorphone (9668) ...............
Alfentanil (9737) ...........................
Remifentanil (9739) ......................
Sufentanil (9740) ..........................
Fentanyl (9801) ............................
Authority: This review is being conducted
under authority of title VII of the Tariff Act
of 1930; this notice is published pursuant to
section 207.62 of the Commission’s rules.
By order of the Commission.
Issued: August 11, 2005.
Marilyn R. Abbott,
Secretary to the Commission.
[FR Doc. 05–16245 Filed 8–16–05; 8:45 am]
BILLING CODE 7020–02–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Registration
By Notice dated March 25, 2005, and
published in the Federal Register on
April 4, 2005 (70 FR 17124–17125),
Mallinckrodt Inc., 3600 North Second
Street, St. Louis, Missouri 63147, made
application by renewal to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
the basic classes of controlled
substances listed in Schedules I and II:
Drug
Schedule
Tetrahydrocannabinols (7370) ......
Codeine-N-oxide (9053) ...............
Dihydromorphine (9145) ...............
Difenoxin (9168) ...........................
Morphine-N-oxide (9307) ..............
1 Commissioner Marcia E. Miller did not
participate in these determinations.
VerDate jul<14>2003
13:34 Aug 16, 2005
Jkt 205001
Schedule
I
I
I
I
I
I
I
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
The company plans to manufacture
the listed controlled substances for
internal use and for distribution to its
customers.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of
Mallinckrodt Inc. to manufacture the
listed basic classes of controlled
substances is consistent with the public
interest at this time. DEA has
investigated Mallinckrodt Inc. to ensure
that the company’s registration is
consistent with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823,
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic classes of controlled
substances listed.
Dated: August 11, 2005.
William J. Walker,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 05–16288 Filed 8–16–05; 8:45 am]
BILLING CODE 4410–09–U
PO 00000
Frm 00073
Fmt 4703
Sfmt 4703
48441
DEPARTMENT OF LABOR
Office of the Secretary
Combating Exploitive Child Labor
Through Education in Indonesia and
Nepal
Bureau of International Labor
Affairs, Department of Labor.
Announcement Type: New. Notice of
Intent To Fund Sole Source Award.
Catalog of Federal Domestic
Assistance (CFDA) Number: Not
applicable.
SUMMARY: The U.S. Department of Labor
(USDOL), Bureau of International Labor
Affairs (ILAB), intends to award USD
2.5 million through a sole source
cooperative agreement to Save the
Children Federation Inc. (STC), a U.S.based non-profit organization. This
funding will be used over a four-year
period to support the current STC
project in Indonesia, ‘‘Enabling
Communities to Combat Child
Trafficking through Education,’’ by
extending project activities in the
earthquake and tsunami stricken region
of Aceh and to bring USDOL funded
child labor activities in Indonesia to a
successful completion. USDOL also
intends to award USD 3.5 million
through a sole source cooperative
agreement to World Education, Inc., a
U.S.-based non-profit organization. This
funding will support a four-year second
phase of World Education’s ‘‘Brighter
Futures Program: Combating Child
Labor in Nepal through Education,’’
because the activity to be funded is
essential to the satisfactory completion
of this project.
ILAB is authorized to award and
administer this program by the
Consolidated Appropriations Act, 2005,
Pub. L. 108–447, 118 Stat. 2809 (2004),
which provided funding for USDOL to
improve access to basic education in
international areas with a high rate of
abusive and exploitative child labor
through the Child Labor Education
Initiative (EI) grant program. Since 1995,
USDOL has awarded grants to
commercial, international, and nongovernmental organizations working to
eliminate the worst forms of child labor
through the provision of basic
education. The cooperative agreements
awarded under this initiative will be
managed by ILAB’s International Child
Labor Program to assure achievement of
the awards’ stated goals.
Indonesia: ILAB finds STC uniquely
qualified to implement a major program
to rapidly restore the educational sector
in Aceh and thereby reduce children’s
vulnerability to trafficking and other
forms of exploitation. STC has worked
AGENCY:
E:\FR\FM\17AUN1.SGM
17AUN1
]]>Agencies
[Federal Register Volume 70, Number 158 (Wednesday, August 17, 2005)]
[Notices]
[Page 48441]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 05-16288]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of Registration
By Notice dated March 25, 2005, and published in the Federal
Register on April 4, 2005 (70 FR 17124-17125), Mallinckrodt Inc., 3600
North Second Street, St. Louis, Missouri 63147, made application by
renewal to the Drug Enforcement Administration (DEA) to be registered
as a bulk manufacturer of the basic classes of controlled substances
listed in Schedules I and II:
------------------------------------------------------------------------
Drug Schedule
------------------------------------------------------------------------
Tetrahydrocannabinols (7370)................................. I
Codeine-N-oxide (9053)....................................... I
Dihydromorphine (9145)....................................... I
Difenoxin (9168)............................................. I
Morphine-N-oxide (9307)...................................... I
Normorphine (9313)........................................... I
Norlevorphanol (9634)........................................ I
Amphetamine (1100)........................................... II
Methamphetamine (1105)....................................... II
Methylphenidate (1724)....................................... II
Codeine (9050)............................................... II
Diprenorphine (9058)......................................... II
Etorphine HCL (9059)......................................... II
Dihydrocodeine (9120)........................................ II
Hydromorphone (9150)......................................... II
Oxycodone (9143)............................................. II
Diphenoxylate (9170)......................................... II
Benzoylecgonine (9180)....................................... II
Hydrocodone (9193)........................................... II
Levorphanol (9220)........................................... II
Meperidine (9230)............................................ II
Methadone (9250)............................................. II
Methadone Intermediate (9254)................................ II
Metopon (9260)............................................... II
Dextropropoxyphene (9273).................................... II
Morphine (9300).............................................. II
Thebaine (9333).............................................. II
Opium extracts (9610)........................................ II
Opium fluid extract (9620)................................... II
Opium tincture (9630)........................................ II
Opium, powdered (9639)....................................... II
Opium, granulated (9640)..................................... II
Levo-alphacetylmethadol (9648)............................... II
Oxymorphone (9652)........................................... II
Noroxymorphone (9668)........................................ II
Alfentanil (9737)............................................ II
Remifentanil (9739).......................................... II
Sufentanil (9740)............................................ II
Fentanyl (9801).............................................. II
------------------------------------------------------------------------
The company plans to manufacture the listed controlled substances
for internal use and for distribution to its customers.
No comments or objections have been received. DEA has considered
the factors in 21 U.S.C. 823(a) and determined that the registration of
Mallinckrodt Inc. to manufacture the listed basic classes of controlled
substances is consistent with the public interest at this time. DEA has
investigated Mallinckrodt Inc. to ensure that the company's
registration is consistent with the public interest. The investigation
has included inspection and testing of the company's physical security
systems, verification of the company's compliance with state and local
laws, and a review of the company's background and history. Therefore,
pursuant to 21 U.S.C. 823, and in accordance with 21 CFR 1301.33, the
above named company is granted registration as a bulk manufacturer of
the basic classes of controlled substances listed.
Dated: August 11, 2005.
William J. Walker,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. 05-16288 Filed 8-16-05; 8:45 am]
BILLING CODE 4410-09-U
